Neuronata-R Phase 3 Signals Hope
Neuronata-R is an autologous stem cell therapy for amyotrophic lateral sclerosis (ALS). However, slow-progressors showed 12-month gains in function and breathing (ALSFRS-R 31.2 vs 26.4; breathing capacity 62.2% vs 50.6%), with lower neurofilament light chain and MCP-1. The company plans a late-2025 FDA Type-C meeting and a 2026 Biologics License Application toward an accelerated path.
Press Release#Amyotrophic Lateral Sclerosis (ALS)#Motor Neurone Disease (MND)